Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Echo Therapeutics Inc. Stories

2013-05-23 16:25:46

Demonstration Followed Stockholders Approval of All Resolutions at Annual Meeting PHILADELPHIA, May 23, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the successful unveiling and demonstration of its Symphony CGM System during a live webcast following yesterday's annual stockholders meeting. Additionally, the...

2013-05-21 08:28:43

PHILADELPHIA, May 21, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, announced today that the Company's clinical trial of its Symphony CGM System has received Institutional Review Board (IRB) approval. The IRB approval enables the commencement of a clinical evaluation of Symphony that will support the Company's CE Mark Technical File....

2013-05-16 08:27:30

Demonstration coincides with Symphony's upcoming CE Mark pivotal trial PHILADELPHIA, May 16, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the unveiling and demonstration of its Symphony CGM System to be used in its regulatory trials. The demonstration will take place during a live webcast following the annual...

2013-05-10 08:24:43

PHILADELPHIA, May 10, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com. (Logo:...

2013-03-18 08:28:44

PHILADELPHIA, March 18, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the year ended December 31, 2012. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com. (Logo:...

2013-03-15 08:26:32

PHILADELPHIA, March 15, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices. (Logo:...

2013-03-13 08:33:28

PHILADELPHIA, March 13, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the appointment of Robert F. Doman to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO) Mr. Doman brings to Echo Therapeutics over 30 years of executive level, international and domestic management, business...

2013-03-12 08:28:45

PHILADELPHIA, March 12, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8,386,027, "Skin Permeation Device For Analyte Sensing or Transdermal Drug Delivery," for the Prelude SkinPrep System, the skin permeation component of the Symphony CGM System....

2013-02-06 12:26:29

PHILADELPHIA, Feb. 6, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the closing of a previously announced underwritten public offering of 13,633,333 shares of its common stock and the full exercise of the over-allotment option to purchase 2,045,000 additional shares, offered at a price to the public of $0.75...

2013-01-31 20:22:22

PHILADELPHIA, Jan. 31, 2013 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony(®) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced the pricing of a previously announced underwritten public offering of 13,333,333 shares of its common stock, offered at a price to the public of $0.75 per share. The gross proceeds to Echo from this offering are expected to be approximately $10.0...